CEREDA, VITTORE
 Distribuzione geografica
Continente #
NA - Nord America 3.094
EU - Europa 161
AS - Asia 57
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.314
Nazione #
US - Stati Uniti d'America 3.094
UA - Ucraina 43
CN - Cina 33
DE - Germania 24
IE - Irlanda 24
IT - Italia 20
GB - Regno Unito 11
FR - Francia 10
PL - Polonia 10
FI - Finlandia 9
KR - Corea 9
JP - Giappone 6
RU - Federazione Russa 4
SE - Svezia 3
SG - Singapore 3
ID - Indonesia 2
NL - Olanda 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
EU - Europa 1
TR - Turchia 1
Totale 3.314
Città #
Woodbridge 1.005
Houston 826
Wilmington 715
Fairfield 104
Ann Arbor 49
Ashburn 48
Chandler 48
Seattle 45
Jacksonville 43
Cambridge 29
Dublin 24
Medford 21
Engelhard 16
Dearborn 15
Kraków 10
Lawrence 9
Hangzhou 6
Rome 6
Beijing 4
Fremont 4
Hefei 4
Kunming 4
San Diego 4
Boston 3
Detroit 3
London 3
Menlo Park 3
Moscow 3
Zhengzhou 3
Brescia 2
Chongqing 2
Falls Church 2
Hanoi 2
Jinan 2
Milan 2
Norwalk 2
Palo Alto 2
Singapore 2
Amsterdam 1
Boardman 1
Chiswick 1
Corleone 1
Guangzhou 1
Hounslow 1
Jakarta 1
Lishui 1
Monte Vista 1
Nanchang 1
Nanjing 1
Novokuznetsk 1
Nuremberg 1
Omaha 1
Paris 1
Southend 1
Southwark 1
Surabaya 1
Sydney 1
Tokyo 1
University Park 1
Venezia 1
Verona 1
Vienna 1
Wenzhou 1
Yoyogi-sanyacho,Tokyo 1
Totale 3.101
Nome #
Immune reaction and colorectal cancer: friends or foes? 414
Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer 413
Effects of conventional therapeutic interventions on the number and function of regulatory T cells 402
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 397
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy 359
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges 349
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients 336
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches 334
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B) 334
Issues and promises of bevacizumab in prostate cancer treatment 16
Totale 3.354
Categoria #
all - tutte 6.106
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.106


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020875 82 76 73 87 76 98 83 69 68 54 47 62
2020/2021471 46 64 44 64 55 49 59 47 13 7 21 2
2021/202278 5 7 3 1 2 8 5 3 5 9 7 23
2022/2023133 11 7 8 12 25 32 6 7 18 0 3 4
2023/202462 13 6 1 0 6 1 28 2 0 0 0 5
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 3.354